Our Leadership

Our Leadership

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Gerry Brunk, MBA

Director

Gerry Brunk, MBA

Gerry Brunk is a Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Since joining Lumira to establish the firm’s Boston office in 2002 he has invested in and served on the boards of directors of over 20 life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Antios Therapeutics, Corvia Medical, Celtaxsys, Engage Therapeutics, KAI Pharmaceuticals (acquired by Amgen) and Endotronix.

Before joining Lumira, Gerry was an entrepreneur who co-founded and served in a variety of management and board capacities at venture capital-funded companies in the pharmacy benefit management, senior living, and technology transfer sectors. Earlier, as an Engagement Manager in the healthcare practice of The Boston Consulting Group, he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, R&D productivity, new product launches, reimbursement and acquisitions. Gerry was also a member of the investment banking group at Credit Suisse First Boston where his clients included public and private healthcare companies.

Gerry holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics. He serves on the board of Southeast BIO, the oversight committee of the Wallace H. Coulter Center for Translational Research at the University of Miami, the review board of the Ivy Foundation Biomedical Innovation Fund at the University of Virginia, and as a mentor for the Canadian Technology Accelerator in Boston and for the Stanford University Biodesign program.

Gerry Brunk, MBA

Director

Gerry Brunk, MBA

Gerry Brunk is a Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Since joining Lumira to establish the firm’s Boston office in 2002 he has invested in and served on the boards of directors of over 20 life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Antios Therapeutics, Corvia Medical, Celtaxsys, Engage Therapeutics, KAI Pharmaceuticals (acquired by Amgen) and Endotronix.

Before joining Lumira, Gerry was an entrepreneur who co-founded and served in a variety of management and board capacities at venture capital-funded companies in the pharmacy benefit management, senior living, and technology transfer sectors. Earlier, as an Engagement Manager in the healthcare practice of The Boston Consulting Group, he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, R&D productivity, new product launches, reimbursement and acquisitions. Gerry was also a member of the investment banking group at Credit Suisse First Boston where his clients included public and private healthcare companies.

Gerry holds an MBA from Stanford University Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics. He serves on the board of Southeast BIO, the oversight committee of the Wallace H. Coulter Center for Translational Research at the University of Miami, the review board of the Ivy Foundation Biomedical Innovation Fund at the University of Virginia, and as a mentor for the Canadian Technology Accelerator in Boston and for the Stanford University Biodesign program.